Bunker Kevin D.'s Form 4 filing
Zentalis Pharmaceuticals, Inc. (ZNTL) · filed Nov 12, 2021
- Accession no.
- 0001725160-21-000222
- Filed
- Nov 12, 2021
- Trade date
- Nov 9-10, 2021
- Filing delay
- 3 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 3 non-derivative transactions. Open-market sales total $781.5K. It was filed 3 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Bunker Kevin D.CIK 0001807484 | Officer (Chief Operating Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 9, 2021 | Common Stock | GGiftDisposed | −240,000 | $0.00 | $0 | 755,067 | Direct | |
| Nov 9, 2021 | Common Stock | GGiftAcquired | +240,000 | $0.00 | $0 | 240,000 | Indirect | |
| Nov 10, 2021 | Common Stock | SSaleDisposed | −10,000 | $78.15 | −$781,500 | 230,000 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.